SURVYR

RXRX

Recursion Pharmaceuticals, Inc.
$3.80
+$0.10 (2.70%)Oct 26 close
Healthcare CompareTechnicals
1M3M6M1Y2Y
-56%-38%-21%-3%+15%Oct 2025Oct 2026Apr 202652w high $6.5052w low $2.77
RXRXSPY
Wall St. Highest PT $10.00 (+163.2%) Wall St. Avg PT $7.32 (+92.5%)
$3$5$7$10$12POC $3Hi $10Avg $7
Underwater Drawdown %Max DD -54.9%Current -39.7%
0.0%-54.9%
Relative Strength vs SPY-52.6% vs SPYUnderperforming
+74%0%-74%
1W
+$0.19 (5.26%)
1M
+$0.06 (1.60%)
3M
+$0.79 (26.25%)
6M
+$0.32 (9.20%)
YTD
−$0.29 (7.09%)
1Y
−$2.24 (37.09%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street analyst consensus
SellHoldStrong Buy
Buy
6 analysts · mean score 2.43
1 = Strong Buy · 5 = Sell
Wall Street consensus
Analyst price targets
Current price$3.80
Average target$7.32
+$3.52 (+92.5%) upsideaverage target vs current price
CurrentAverageMedian
Low$4.00
Median$7.32
High$10.00
12-month Wall Street target range

Third-party ratings, not SURVYR.'s views.

Key stats & company

Market value$2.0B
P/E (next 12 months, estimated)-4.2
52-week range$2.77 – $6.50
Revenue growth (latest quarter vs a year ago)-60.1%
Dividend yieldNo dividend
Analyst consensusBuy (6)
Average analyst price target$7.32 (+93%)

What they do

Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis.

Healthcare · Biotechnology
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

No sector grades for RXRX yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 SURVYR. Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
 SURVYR. Long Book
Not in the current book

Earnings & events

RXRX earningsNext report in 6 days
Next report
Mon Nov 2, 2026Time not confirmed
EPS consensus-$0.23
Revenue consensus–
Last 4 quarters · EPS vs estimate
Aug 5, 2026-$0.25est -$0.23−6.8%Below estimates
May 6, 2026-$0.22est -$0.26+14.4%Above estimates
Feb 25, 2026-$0.21est -$0.32+33.3%Above estimates
Nov 5, 2025-$0.36est -$0.38+5.7%Above estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · refreshed 2026-10-26 18:46:20 ET
24-1125-0225-0525-0825-1126-0226-0526-08-0.530.00
EstimateActual (beat)Actual (miss)

News & catalysts

More news
Meta Stock Gets $24 Million Vote of Confidence From Cathie Wood
GuruFocus.com · Oct 19
Tempus AI Expands Strategic Collaborations to Drive Future Growth
Zacks · Oct 12
Insider trades
Hershberg Robert
Director · 2026-10-06
Sell
$125.0K
Borgeson Blake
Director · 2026-10-06
Sell
$242.0K
Khan Najat
Director, CEO and President · 2026-09-08
Sell
$78.8K
Borgeson Blake
Director · 2026-09-01
Sell
$100.2K
Borgeson Blake
Director · 2026-08-04
Sell
$97.5K
None
None · None
Sell
–
None
None · None
Sell
–
None
None · None
Sell
–
None
None · None
Sell
–
None
None · None
Sell
–
None
None · None
Sell
–

Stats refreshed 2026-10-26 18:46:20 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026